Tealwood Asset Management Inc. Makes New Investment in Eli Lilly and Company $LLY

Key Points

• Tealwood Asset Management Inc. acquired 1,788 shares of Eli Lilly and Company (NYSE: LLY), valued at approximately $1.39 million, during the second quarter.
• Equities analysts have varied ratings for Eli Lilly, with a current average rating of "Moderate Buy" and an average price target of $939.61.
• Eli Lilly reported a strong earnings performance for the last quarter, with EPS of $6.31, surpassing estimates and showing a year-over-year revenue increase of 37.6%.

Tealwood Asset Management Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,788 shares of the company's stock, valued at approximately $1,394,000.

Other hedge funds also recently bought and sold shares of the company. Duquesne Family Office LLC lifted its holdings in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after buying an additional 32,640 shares during the period. Corient IA LLC purchased a new stake in Eli Lilly and Company during the first quarter worth $570,000. LS Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP acquired a new position in shares of Eli Lilly and Company during the first quarter worth $14,866,000. Finally, Prism Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the first quarter worth $207,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LLY shares. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Price Performance

NYSE LLY opened at $725.54 on Tuesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock's fifty day moving average price is $733.42 and its 200 day moving average price is $765.98. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The company has a market cap of $686.69 billion, a price-to-earnings ratio of 47.42, a PEG ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $3.92 EPS. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.